Myasthenia Gravis

May 1st 2024

COVID-19 and worsening myasthenia gravis (MG) were the most common treatment-emergent adverse events, the study found.

April 27th 2024

Over a median follow-up time of nearly 3 years, three-fourths (72.8%) of patients with myasthenia gravis (MG) were hospitalized and half visited the accident and emergency department.

April 19th 2024

A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.

April 15th 2024

A new survey has found that most patients who have generalized myasthenia gravis who switched from eculizumab to ravulizumab preferred the latter.